Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Clinical trial agreements can almost always be negotiated. Most part-time investigators, however, do not have the necessary legal expertise or time to interpret the agreement and conduct an effective negotiation. Proper legal representation at present requires an attorney who is expert in this very specialized field. Because sponsor negotiators often have huge backlogs of contracts in process, and over half of part-time investigators do not negotiate (or even read) the clinical trial agreement, an investigator who opens a negotiation may never emerge from the queue.
A New System
A new system to help negotiators is now in the works. Over 200 sites, sponsors, contract research organizations (CROs), and site management organizations (SMOs) have joined together in MAGI, the Model Agreement Group Initiative. MAGI is developing a very flexible “multiple-choice” model clinical trial agreement to streamline negotiations in the U.S. and internationally. MAGI's growing membership includes representatives from over two-thirds of U.S. News & World Report's Top-50 Research Medical Schools and Honor Roll hospitals, many of the largest SMOs, the four largest CROs (eight of the top nine), two of the top four biotechs, and a number of smaller and mid-sized pharmaceutical companies.
One of MAGI's objectives is to educate both parties in the negotiation. Its model clinical trial agreement will therefore be accompanied by commentary, explaining the implications of the contract text. Attorneys who may not specialize in these types of contracts will be able to gain valuable insights, and even negotiators without legal expertise will become much more effective.
MAGI members help draft one of 90 sections of the model agreement. Membership is free and there is no obligation to use the resulting model agreement. MAGI co-manages a biannual educational conference, offers professional Clinical Research Contract Professional (CRCP) certification, and publishes a semi-weekly e-newsletter. More information is available at www.firstclinical.com/magi.
Good News for Clinical Investigators
It's best to be prepared for the worst, but the news is not all bad for clinical investigators. To start with, only a small percentage of the over 2.3 million subjects who take part in studies each year in the U.S. are injured during clinical trials. Only a small percentage of those injured have a legitimate cause of action against the investigator or sponsor. Most legitimate causes of action (and many that are not legitimate) are resolved quickly and economically. It's a cost of doing business for sponsors, and they generally prefer to avoid publicity.
The number of cases that reach trial will probably increase over time, but today, very few do. Of these, defendants have a good batting average in winning. The best litigation is, of course, litigation that never occurs. Research hospitals have the expertise and financial resources to protect themselves. In addition to taking part in the MAGI project or something similar, independent physicians can take several steps to protect themselves from the risk of liability claims by injured study subjects:
Clinical trial agreements can almost always be negotiated. Most part-time investigators, however, do not have the necessary legal expertise or time to interpret the agreement and conduct an effective negotiation. Proper legal representation at present requires an attorney who is expert in this very specialized field. Because sponsor negotiators often have huge backlogs of contracts in process, and over half of part-time investigators do not negotiate (or even read) the clinical trial agreement, an investigator who opens a negotiation may never emerge from the queue.
A New System
A new system to help negotiators is now in the works. Over 200 sites, sponsors, contract research organizations (CROs), and site management organizations (SMOs) have joined together in MAGI, the Model Agreement Group Initiative. MAGI is developing a very flexible “multiple-choice” model clinical trial agreement to streamline negotiations in the U.S. and internationally. MAGI's growing membership includes representatives from over two-thirds of U.S. News & World Report's Top-50 Research Medical Schools and Honor Roll hospitals, many of the largest SMOs, the four largest CROs (eight of the top nine), two of the top four biotechs, and a number of smaller and mid-sized pharmaceutical companies.
One of MAGI's objectives is to educate both parties in the negotiation. Its model clinical trial agreement will therefore be accompanied by commentary, explaining the implications of the contract text. Attorneys who may not specialize in these types of contracts will be able to gain valuable insights, and even negotiators without legal expertise will become much more effective.
MAGI members help draft one of 90 sections of the model agreement. Membership is free and there is no obligation to use the resulting model agreement. MAGI co-manages a biannual educational conference, offers professional Clinical Research Contract Professional (CRCP) certification, and publishes a semi-weekly e-newsletter. More information is available at www.firstclinical.com/magi.
Good News for Clinical Investigators
It's best to be prepared for the worst, but the news is not all bad for clinical investigators. To start with, only a small percentage of the over 2.3 million subjects who take part in studies each year in the U.S. are injured during clinical trials. Only a small percentage of those injured have a legitimate cause of action against the investigator or sponsor. Most legitimate causes of action (and many that are not legitimate) are resolved quickly and economically. It's a cost of doing business for sponsors, and they generally prefer to avoid publicity.
The number of cases that reach trial will probably increase over time, but today, very few do. Of these, defendants have a good batting average in winning. The best litigation is, of course, litigation that never occurs. Research hospitals have the expertise and financial resources to protect themselves. In addition to taking part in the MAGI project or something similar, independent physicians can take several steps to protect themselves from the risk of liability claims by injured study subjects:
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
End of year collections are crucial for law firms because they allow them to maximize their revenue for the year, impacting profitability, partner distributions and bonus calculations by ensuring outstanding invoices are paid before the year closes, which is especially important for meeting financial targets and managing cash flow throughout the firm.
Law firms and companies in the professional services space must recognize that clients are conducting extensive online research before making contact. Prospective buyers are no longer waiting for meetings with partners or business development professionals to understand the firm's offerings. Instead, they are seeking out information on their own, and they want to do it quickly and efficiently.
Through a balanced approach that combines incentives with accountability, firms can navigate the complexities of returning to the office while maintaining productivity and morale.
The paradigm of legal administrative support within law firms has undergone a remarkable transformation over the last decade. But this begs the question: are the changes to administrative support successful, and do law firms feel they are sufficiently prepared to meet future business needs?
Counsel should include in its analysis of a case the taxability of the anticipated and sought after damages as the tax effect could be substantial.